Nanomedicine News

RSS

Celsion’s TheraSilence Technology Effectively Delivers miR-145 Inhibitor in Well-Established PAH Model

Celsion Corporation, a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today reported the publication of an abstract in the prestigious Journal of Controlled Release summarizing findings from a preclinical study confirming effective delivery of RNA to lung cells.

18 May 2015

Therapeutic Cells Encapsulated in Nanoporous Capsules Can Treat from Within Tumors

Attacking the perennial problem of systemic toxicity from typical chemotherapy treatments, Dartmouth investigators, led by Barjor Gimi, PhD, have engineered therapeutic cells encapsulated in nanoporous capsules to secrete antitumor molecules from within the tumor.

15 May 2015

Dicerna Adds PNET Expansion Cohort to DCR-MYC Phase 1 Study in Solid Tumors, Multiple Myeloma or Lymphoma

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients.

15 May 2015

Phase Ib GEN-1 Trial for Platinum-Resistant Ovarian Cancer to be Presented at 2015 ASCO

Celsion Corporation, a fully integrated oncology drug development company, today announced that results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented in poster session at the 2015 American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday, May 30th. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein

14 May 2015

ASCO Annual Meeting 2015: Dicerna to Present New Data from DCR-MYC Phase 1 Study in Patients with Solid Tumors

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2, 2015 in Chicago.

14 May 2015

Sanofi Exercises Option to Exclusive License to Develop Immunotherapy for Celiac Disease Treatment

Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease.

14 May 2015

Nanoparticles Combined with Potent Disrupter Can Help Prevent Spread of Triple-Negative Breast Cancer

Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.

13 May 2015

3D Bioprinter May Help Make Synthesized Nerve Tissue Using Nanotechnology-Inspired Material

The printer looks like a toaster oven with the front and sides removed. Its metal frame is built up around a stainless steel circle lit by an ultraviolet light. Stainless steel hydraulics and thin black tubes line the back edge, which lead to an inner, topside box made of red plastic.

13 May 2015

Panacea Selects Goodwin Biotechnology for Nanoparticle Cancer Vaccine Stability Testing and Fill / Finish Project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization (CDMO) that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) â-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

12 May 2015

Cologne University Hospital Initiates MagForce NanoTherm Therapy in Commercial Setting for Brain Cancer Treatment

MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Center for Integrated Oncology at Cologne University Hospital, headed by Prof. Dr. med. Roland Goldbrunner, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers in addition to the ongoing post-marketing study.

8 May 2015

Nanomedicine News

Celsion’s TheraSilence Technology Effectively Delivers miR-145 Inhibitor in Well-Established PAH Model

Therapeutic Cells Encapsulated in Nanoporous Capsules Can Treat from Within Tumors

Dicerna Adds PNET Expansion Cohort to DCR-MYC Phase 1 Study in Solid Tumors, Multiple Myeloma or Lymphoma

Phase Ib GEN-1 Trial for Platinum-Resistant Ovarian Cancer to be Presented at 2015 ASCO

ASCO Annual Meeting 2015: Dicerna to Present New Data from DCR-MYC Phase 1 Study in Patients with Solid Tumors

Sanofi Exercises Option to Exclusive License to Develop Immunotherapy for Celiac Disease Treatment

Nanoparticles Combined with Potent Disrupter Can Help Prevent Spread of Triple-Negative Breast Cancer

3D Bioprinter May Help Make Synthesized Nerve Tissue Using Nanotechnology-Inspired Material

Panacea Selects Goodwin Biotechnology for Nanoparticle Cancer Vaccine Stability Testing and Fill / Finish Project

Cologne University Hospital Initiates MagForce NanoTherm Therapy in Commercial Setting for Brain Cancer Treatment

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting